LTS Lohmann Therapie-Systeme AG
LTS Lohmann Therapie-Systeme AG, commonly referred to as LTS, is a leading global player in the pharmaceutical and medical device industry, headquartered in Andernach, Germany. Founded in 1981, the company has established itself as a pioneer in transdermal drug delivery systems, offering innovative solutions that enhance patient compliance and therapeutic efficacy. With a strong presence in Europe, North America, and Asia, LTS focuses on the development and manufacturing of advanced drug delivery technologies, including patches and films. Their unique approach combines cutting-edge research with state-of-the-art production capabilities, ensuring high-quality products tailored to meet diverse medical needs. Recognised for its commitment to excellence, LTS has achieved significant milestones, solidifying its market position as a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does LTS Lohmann Therapie-Systeme AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
LTS Lohmann Therapie-Systeme AG's score of 35 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
LTS Lohmann Therapie-Systeme AG's reported carbon emissions
LTS Lohmann Therapie-Systeme AG, headquartered in Germany, has set ambitious climate commitments aimed at achieving net-zero greenhouse gas emissions across its value chain by 2050. Although specific emissions data for the most recent year is not available, the company has established significant reduction targets. Starting in 2023, LTS aims to reduce its absolute Scope 1 and Scope 2 emissions by 50% by 2030, with a long-term goal of a 90% reduction by 2050. Additionally, the company is committed to reducing its absolute Scope 3 emissions—which encompass emissions from purchased goods and services, fuel- and energy-related activities, waste generated in operations, employee commuting, and end-of-life treatment of sold products—by 25% by 2030 and 90% by 2050. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit temperature rise to 1.5°C. LTS Lohmann Therapie-Systeme AG's proactive approach reflects its commitment to sustainability and responsible environmental stewardship within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
LTS Lohmann Therapie-Systeme AG is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
